You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/71995
Full metadata record
DC FieldValueLanguage
dc.contributor.authorReddy, K. Rajender-
dc.contributor.authorShiffman, Mitchell L.-
dc.contributor.authorRodrigueztorres, Maribel-
dc.contributor.authorCheinquer, Hugo-
dc.contributor.authorAbdurakhmanov, Djamal-
dc.contributor.authorBakulin, Igor-
dc.contributor.authorMorozov, Viacheslav-
dc.contributor.authorSilva, Giovanni Faria-
dc.contributor.authorGeyvandova, Natalia-
dc.contributor.authorStanciu, Carol-
dc.contributor.authorRabbia, Michael-
dc.contributor.authorMcKenna, Michael-
dc.contributor.authorThommes, James A.-
dc.contributor.authorHarrison, Stephen A.-
dc.date.accessioned2014-05-27T11:24:51Z-
dc.date.accessioned2016-10-25T18:30:27Z-
dc.date.available2014-05-27T11:24:51Z-
dc.date.available2016-10-25T18:30:27Z-
dc.date.issued2010-12-01-
dc.identifierhttp://dx.doi.org/10.1053/j.gastro.2010.08.051-
dc.identifier.citationGastroenterology, v. 139, n. 6, p. 1972-1983, 2010.-
dc.identifier.issn0016-5085-
dc.identifier.urihttp://hdl.handle.net/11449/71995-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/71995-
dc.description.abstractBackground & Aims Patients infected with hepatitis C virus (HCV) genotype 1, body weight <85 kg, and high baseline viral load respond poorly to standard doses of pegylated interferon (peginterferon) and ribavirin. We evaluated intensified therapy with peginterferon alfa-2a plus ribavirin. Methods This double-blind randomized trial included HCV genotype 1-infected outpatients from hepatology clinics with body weight <85 kg and HCV RNA titer <400,000 IU/mL. Patients were randomized to 180 μg/wk peginterferon alfa-2a for 48 weeks plus 1200 mg/day ribavirin (standard of care) (group A, n = 191) or 1400/1600 mg/day ribavirin (group B, n = 189). Additional groups included 360 μg/wk peginterferon alfa-2a for 12 weeks then 180 μg/wk peginterferon alfa-2a for 36 weeks plus 1200 mg/day ribavirin (group C, n = 382) or 1400/1600 mg/day ribavirin (group D, n = 383). Follow-up lasted 24 weeks after treatment. Results Sustained virologic response rates (HCV RNA level <15 IU/mL at end of follow-up) in groups A, B, C, and D were 38%, 43%, 44%, and 41%, respectively. There were no significant differences among the 4 groups or between pooled peginterferon alfa-2a regimens (A + B vs C + D: odds ratio [OR], 1.08; 95% confidence interval [CI], 0.831.39; P = .584) or pooled ribavirin regimens (A + C vs B + D: OR, 1.00; 95% CI, 0.791.28; P = .974). Conclusions In patients infected with HCV genotype 1 who are difficult to treat (high viral load, body weight <85 kg), a 12-week induction regimen of peginterferon alfa-2a and/or higher-dose ribavirin is not more effective than the standard regimen. © 2010 AGA Institute.en
dc.format.extent1972-1983-
dc.language.isoeng-
dc.sourceScopus-
dc.subjectChronic Hepatitis C-
dc.subjectSteatosis and Response to HCV Therapy-
dc.subjectTolerability of High-Dose Pegylated Interferon-
dc.subjectTolerability of High-Dose Ribavirin-
dc.subjectcolony stimulating factor-
dc.subjectpeginterferon alpha2a-
dc.subjectribavirin-
dc.subjectvirus RNA-
dc.subjectadult-
dc.subjectalopecia-
dc.subjectanemia-
dc.subjectarthralgia-
dc.subjectasthenia-
dc.subjectbody weight-
dc.subjectchill-
dc.subjectclinical trial-
dc.subjectcontrolled clinical trial-
dc.subjectcontrolled study-
dc.subjectcoughing-
dc.subjectdecreased appetite-
dc.subjectdepression-
dc.subjectdiarrhea-
dc.subjectdizziness-
dc.subjectdouble blind procedure-
dc.subjectdrug dose reduction-
dc.subjectdrug efficacy-
dc.subjectdrug eruption-
dc.subjectdrug fever-
dc.subjectdrug induced headache-
dc.subjectdrug megadose-
dc.subjectdrug withdrawal-
dc.subjectfatigue-
dc.subjectfemale-
dc.subjectfollow up-
dc.subjectgenotype-
dc.subjecthemoglobin blood level-
dc.subjecthepatitis C-
dc.subjecthuman-
dc.subjectinsomnia-
dc.subjectirritability-
dc.subjectmajor clinical study-
dc.subjectmale-
dc.subjectmediastinum disease-
dc.subjectmulticenter study-
dc.subjectmyalgia-
dc.subjectnausea-
dc.subjectneutrophil count-
dc.subjectoutpatient-
dc.subjectpneumonia-
dc.subjectpriority journal-
dc.subjectpruritus-
dc.subjectrandomized controlled trial-
dc.subjectrespiratory tract disease-
dc.subjectside effect-
dc.subjectthorax disease-
dc.subjectthrombocyte count-
dc.subjecttreatment duration-
dc.subjectvirus load-
dc.subjectAdult-
dc.subjectAntiviral Agents-
dc.subjectBody Weight-
dc.subjectDose-Response Relationship, Drug-
dc.subjectDrug Therapy, Combination-
dc.subjectFatty Liver-
dc.subjectFemale-
dc.subjectGenotype-
dc.subjectHepacivirus-
dc.subjectHepatitis C, Chronic-
dc.subjectHumans-
dc.subjectInterferon Alfa-2a-
dc.subjectMale-
dc.subjectMiddle Aged-
dc.subjectObesity-
dc.subjectPolyethylene Glycols-
dc.subjectRibavirin-
dc.subjectViral Load-
dc.titleInduction pegylated interferon Alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loadsen
dc.typeoutro-
dc.contributor.institutionUniversity of Pennsylvania-
dc.contributor.institutionBon Secours Health System-
dc.contributor.institutionFundacion de Investigacion de Diego Santurce-
dc.contributor.institutionHospital de Clinicas de Porto Alegre-
dc.contributor.institutionMoscow Medical Academy-
dc.contributor.institutionGastroenterology Department-
dc.contributor.institutionMinistry of Defense of the Russian Federation-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.contributor.institutionNo. 1 Stavropol State Medical Academy-
dc.contributor.institutionGastroenterology and Hepatology Institute-
dc.contributor.institutionRoche-
dc.contributor.institutionBrooke Army Medical Center-
dc.description.affiliationDivision of Gastroenterology University of Pennsylvania, Philadelphia, PA-
dc.description.affiliationLiver Institute of Virginia Bon Secours Health System, Newport News, VA-
dc.description.affiliationFundacion de Investigacion de Diego Santurce, Santurce-
dc.description.affiliationHospital de Clinicas de Porto Alegre, Porto Alegre-
dc.description.affiliationMoscow Medical Academy, Moscow-
dc.description.affiliationGastroenterology Department, Samara-
dc.description.affiliationState Postgraduate Medical Institute Ministry of Defense of the Russian Federation, Moscow-
dc.description.affiliationBotucatu School of Medicine, Botucatu-
dc.description.affiliationNo. 1 Stavropol State Medical Academy, Stavropol-
dc.description.affiliationGastroenterology and Hepatology Institute, Iasi-
dc.description.affiliationRoche, Nutley, NJ-
dc.description.affiliationRoche, Welwyn-
dc.description.affiliationBrooke Army Medical Center, Houston, TX-
dc.identifier.doi10.1053/j.gastro.2010.08.051-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofGastroenterology-
dc.identifier.scopus2-s2.0-78649715862-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.